PRB 00-35E
REPRODUCTIVE TECHNOLOGIES:
SURROGACY, AND EGG AND SPERM DONATION
Prepared by:
Sonya Norris
Science and Technology Division
8 February 2001
TABLE
OF CONTENTS
INTRODUCTION
GAMETE
DONATION
A. Sperm Donation
B. Egg Donation
SURROGACY
A. Reasons for Surrogate Use
B. Commercial vs.
Non-commercial Arrangements
C. Genetic vs. Gestational
Surrogate
D. Issues Raised
When Considering Surrogacy
1. Arguments
Against Pre-conception Arrangements
2. Arguments
in Support of Pre-conception Arrangements
E. Regulation of Surrogacy
in Canada
CHRONOLOGY
OF CANADAS ACTIONS WITH RESPECT TO NRTS
CONCLUSION
SELECTED REFERENCES
REPRODUCTIVE
TECHNOLOGIES:
SURROGACY, AND EGG AND SPERM DONATION
INTRODUCTION
Twenty
years ago, the only reproductive technologies available to infertile couples
were artificial insemination and in vitro fertilization.
In the past two decades, there has been an explosion of reproductive
and genetic technologies that can offer a multitude of options both to
infertile couples and to those not wanting to pass on inheritable conditions
to their offspring. The
scientific, medical, ethical and legal communities have struggled to keep
pace with the challenges posed by these advances.
Many
of the new reproductive technologies (NRTs) available are briefly described
in Reproductive Infertility: Prevalence, Causes, Trends and Treatment,
a 2001 Library of Parliament publication. This paper will provide
an overview of the practices of donating gametes (eggs and sperm) and
surrogacy, and will outline the steps taken by Canada thus far to regulate
these practices.
GAMETE DONATION
Gametes the reproductive
cells of both men and women are the male sperm and the female eggs
(or ova). Sperm, or semen, banks for donated
sperm have been in existence for a number of years as donated sperm was
requested for use in artificial insemination and in vitro fertilization
procedures. Egg donation,
however, is a much more recent phenomenon due to the significantly more
elaborate techniques required to extract eggs from a womans ovaries.
A. Sperm Donation
The
only regulation of reproductive technologies in Canada at this time is
for the donation of semen samples for use in artificial insemination or
in vitro fertilization. The 1996 Semen
Regulations (The Processing
and Distribution of Semen for Assisted Conception Regulations) of
the Food and Drugs Act were updated in
March 2000. Semen falls within the definition
of a drug if it is used for assisted conception.
Semen
donors are usually anonymous and undergo rigorous screening for medical
and genetic diseases for all sexually transmitted and other infectious
diseases including AIDS and hepatitis. All donations must be quarantined
for six months and the donor re-tested at this time to ensure samples
are negative for the viruses which lead to these diseases.
The Semen Regulations also stipulate that if a donated sample has
a high white blood cell count, it must be destroyed, as this is often
indicative of a viral or bacterial infection. Potential recipients of donated sperm
can obtain non-identifying information of the donor including his personal
and family health history.
Donations
of sperm may be requested to overcome infertility in couples where the
man has no sperm production or the sperm count is so low that pregnancy
is improbable. Single women and lesbian couples also
take advantage of donated sperm in order to conceive.
In
July 1999, Health Canada recommended that recipients of donated sperm
should be notified and advised to be re-tested for a number of infectious
agents. This recommendation followed a Health
Canada inspection of Canadian semen banks, which revealed deficiencies
in testing as well as non-compliance with regulations.
The
discovery of these inconsistencies also resulted in Health Canada directing
all non-compliant sperm banks to quarantine all affected donations until
they could prove their compliance. Health Canada also initiated
at this time, in collaboration with the Canadian Fertility and Andrology
Society and the Canadian Standards Association, a review of the guidelines
in the Semen Regulations. The updated testing requirements came
into effect 14 March 2000. Some of the more significant changes
to these regulations included mandatory screening of donors for transmissible
spongiform encephalopathies (including Creutzfeldt-Jakob Disease) and
for encephalitis.
B. Egg Donation
Egg
donation is a product of in vitro fertilization (IVF) technology.
In IVF, multiple eggs are stimulated to grow via hormone
therapy (controlled ovarian hyperstimulation) and are then harvested from
the woman. Retrieval of the eggs requires sedation
as the eggs are removed vaginally with the use of a needle.
The mature eggs are subsequently fertilized outside of the
body and allowed to grow for a few days.
The resulting embryos are then inserted into the uterus (a maximum
of three, usually) and will be followed by implantation and pregnancy
if the procedure is successful.
The
egg harvesting technique developed for IVF has subsequently been used
for the donation of eggs, in the same way as sperm has been used for donation
purposes for decades. Donated eggs, from either known or
anonymous donors, can be used to overcome infertility in women who:
lack ovaries; have diminished ovarian function; or have
a genetic disease or a history of genetic disease.
Egg
donation, however, is considerably more complicated than sperm donation. In addition to the complex procedure
for egg harvesting, eggs are also less amenable to storage than are sperm. Unlike the banking of sperm donations,
no such banks exist for egg donations.
Eggs are used immediately after retrieval and are fertilized
in vitro. Resulting embryos are more easily
stored than eggs and can either be implanted or stored cryogenically for
an extended period of time.
Potential
egg donors are carefully screened before being accepted.
Most clinics require volunteers to submit to:
-
a physical examination;
-
blood tests for infectious
agents and cervical cultures to test for sexually transmitted diseases;
-
a medical history (personal
and family); and
-
psychosocial evaluation
both for the health of the donated gametes and to evaluate the psychological
impact on the donor of giving up gametes.
Many
fertility clinics in Canada offer egg donation services. Although
Canada has no legislation to deal with egg donation, some clinics adhere
to the wording of Bill C-47, the reproductive technologies legislation
that died on the Order Paper when the 1997 federal election was
called. This legislation would have prohibited the commercialization
of egg donation. Although it did not prohibit the practice of egg
donation, the legislation would have prohibited the payment of anonymous
egg donors and the advertisement of such services. The bartering
system is in use in some fertility clinics. In some cases, women
are offered IVF services in exchange for some of their eggs. Many
argue that this practice exploits less affluent women. On the other
hand, IVF patients are already committed to the egg retrieval process,
unlike anonymous volunteers who are exposed to a certain amount of risk
with no personal gain.
SURROGACY
Surrogacy is also referred
to as a pre-conception arrangement, or contract motherhood, and is one
of the more ethically volatile categories of the NRTs.
Although this practice is not as common in Canada as it is in the
United States, a number of Canadian fertility clinics offer the service
or counselling with this approach. There are different types of arrangements. The surrogate may either be artificially
inseminated with the sperm of the commissioning father and will become
the genetic mother (genetic surrogate), or she may have an embryo produced
through IVF of the commissioning couples gametes, in which case the surrogate
provides only the womb for gestation and makes no genetic contribution
(gestational surrogate). The
surrogate arrangement may or may not involve the use of a broker, or lawyer,
with accompanying fees.
A.
Reasons for Surrogate Use
Women who are unable to overcome
their infertility through other NRTs may opt for use of a gestational
or genetic surrogate in order to obtain an infant.
Some medical conditions such as diabetes, heart problems
or severe high blood pressure may also prevent an otherwise fertile
woman from carrying a baby to term. However, most people have heard accounts
of surrogates being commissioned simply because the commissioning couple
does not wish to submit to the months of pregnancy and labour of delivery. There is little, if any, existing documentation on which to
estimate the proportion of each of these, or other, reasons.
B. Commercial vs. Non-commercial
Arrangements
These
two categories of surrogacy essentially separate the purely altruistic
practice from the business arrangement.
In commercial pre-conception arrangements, the surrogate receives
payment for her services in the form of fees and expenses.
In non-commercial arrangements, frequently between family members
or close friends, one woman offers to carry a baby for the other, with
no contract required and no financial compensation requested.
C. Genetic vs. Gestational
Surrogate
A
genetic surrogate essentially donates her own egg and is inseminated with
the sperm of the commissioning man.
This sort of surrogacy has been used, in some form, since the beginning
of time. Women who have
had hysterectomies, or perhaps are older, or have experienced premature
menopause may elect to solicit a genetic surrogate.
A
gestational surrogate has an embryo inserted into her uterus following
IVF. The embryo is produced with the egg and sperm of the commissioning
couple, or in some cases, donated gametes. A couple may choose to
request a gestational surrogate when the woman has no uterus or is unable
to carry a pregnancy to term. Success rates of pregnancy are generally
higher for artificial insemination than for IVF, and therefore by extension
genetic surrogacy is generally more successful than gestational surrogacy.
D. Issues Raised When
Considering Surrogacy
1. Arguments Against
Pre-conception Arrangements
Surrogacy
is much more common in the United States than it is in Canada. Arguments against the practice therefore
frequently draw upon the U.S. experience.
Some people believe that pre-conception agreements, specifically
commercial ones, have the potential to exploit women.
Typically these arrangements are between older, well-educated and
affluent commissioning couples and younger, less educated and poor women. Many feel that this will exploit the women who will be lured
by the fees offered but who will not appreciate the risks involved, both
physical and psychological. The U.S. experience also suggests
that surrogates may be imported from other countries solely
for the purpose of surrogacy and then subsequently returned to that country.
Another
issue raised by those who oppose the practice of surrogacy is the commodification
of babies. Those who oppose the practice contend
that, simply stated, a commercial pre-conception arrangement is a business
transaction in which a child is a product that is sold by the surrogate
and purchased by the commissioning couple, or individual. Many suggest that inevitably there will be commissioning couples
who will refuse to accept the infant if it doesnt meet their specifications.
Some
see pre-conception arrangements as a means of marketing reproduction.
The practice attempts to attach a commercial value on the reproductive
process and by extrapolation, on a woman in her capacity to reproduce.
Opponents of surrogacy see these and other issues as harmful to individuals,
families and society. They feel that ultimately legitimizing the
practice would result in a lack of respect for the sanctity of life.
2. Arguments
in Support of Pre-conception Arrangements
Supporters
of surrogacy argue that the practice provides a valuable option to women
who are medically unable to carry a child.
Many people believe that surrogacy is merely another way to treat
infertility. Others feel
that couples have the right to reproduce without the interference of government
and that a woman has the right to choose to be a surrogate if she gives
informed consent.
Some
people believe that commercial arrangements should be separated from the
non-commercial ones. They suggest that although commercial pre-conception
arrangements may be unacceptable, the altruistic practice should be permitted
as it does not commodify infants or exploit underprivileged women like
its commercial counterpart.
E. Regulation of Surrogacy in
Canada
At
this time, surrogacy is not regulated by legislation.
Although surrogacy is legal in Canada, fertility clinics advise
clients to seek legal counsel before entering any surrogacy agreements.
Health Canada produced a discussion paper in 2000, outlining proposed
prohibited practices for a proposed reproductive technologies bill.
This would have included commercial surrogacy the practice
itself, advertising for it, or being a broker or lawyer affiliated with
it. At this time, any contract
produced for a commercial surrogacy arrangement can be enforced through
contract law.
CHRONOLOGY
OF CANADAS ACTIONS WITH RESPECT TO NRTS
Since
the 1993 Royal Commission on New Reproductive Technologies report, the
federal government has taken several actions, but few with any regulatory
outcome. These include:
1993-1996
Federal/Provincial/Territorial Working Group on Reproductive and
Genetic Technologies (RGT) was established to advise the Deputy Ministers
of Health.
1995
Interim moratorium on specific RGTs was announced; this voluntary
moratorium applied to: buying and selling of eggs, sperm
and embryos; egg donation in exchange for in vitro fertilization
services; germ-line genetic alteration; human embryo cloning; retrieval
of eggs from cadavers and fetuses, etc.
1996
Advisory Committee on Reproductive and Genetic Technologies was
established to advise Health Canada on moratorium compliance and other
developments.
1996
Regulations for the processing and distribution of semen for assisted
conception implemented.
1996
Bill C-47, The Human Reproductive and Genetic Technologies Act,
was introduced to prohibit unacceptable RGT practices including the commercialization
of gametes and embryos, surrogacy, cloning, non-medical sex selection,
maintenance of embryos outside the womb, post-mortem retrieval of gametes,
embryo transfer between human and other animals, research on gametes or
embryos without donor consent, etc.
1996
Minister of Health released a discussion paper entitled New
Reproductive and Genetic Technologies:
Setting Boundaries, Enhancing Health, proposing a regulatory
framework for national standards on permissible practices such as in
vitro fertilization, donor insemination, use of fetal tissue, storage
and donation of gametes and embryos, and embryo research including pre-implantation
diagnosis.
1997
Bill C-47 died on the Order Paper at the call of the 1997
federal election.
1997
Canada signed the UNESCO Universal Declaration on the Human Genome
and Human Rights, which also agreed with the G-7 position on the need
for a prohibition of nuclear transfer for human cloning.
1998
Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans produced by the
Medical Research Council, the Natural Sciences and Engineering Research
Council, and the Social Sciences and Humanities Research Council.
1999
Health Canada issued an overview paper on reproductive and genetic
technologies (RGTs) to further the discussion on the proposed approach
and management of a regulatory framework.
2000
Guidelines for semen donation were updated.
2000
Health Canada produced a discussion paper regarding possible new
legislation dealing with RGTs.
CONCLUSION
This paper has offered an
overview of gamete donation and pre-conception arrangements. Although sperm donation and pre-conception arrangements, in
various forms, have been practised for some time, egg donation is a relatively
new option. In Canada, at
this time, sperm donation and storage is the only one of these practices
which is regulated and this comes under the authority of the Food and Drugs Act.
SELECTED REFERENCES
Health
Canada.
-
Potential
risks of disease transmission by donated semen.
News release. July 1999.
-
Guidance
for the Interpretation of Sections 2 to 5 of the Canadian Fertility
and Andrology Society 2000 Guidelines for Therapeutic Donor Insemination. Ottawa:
Therapeutic Products Programme, Health Canada, 25 May
2000.
Norris,
Sonya. Reproductive Infertility: Prevalence, Causes, Trends and Treatments. In Brief (PRB 00-32E). Ottawa:
Parliamentary Research Branch, Library of Parliament, 2 January 2001.
Royal
Commission on New Reproductive Technologies. Proceed With Care. Final Report. Ottawa: Minister
of Government Services Canada, 1993.
Websites.
|